Cargando…

Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies

Can genetic and clinical findings made in a single patient be considered sufficient to establish a causal relationship between genotype and phenotype? We report that up to 49 of the 232 monogenic etiologies (21%) of human primary immunodeficiencies (PIDs) were initially reported in single patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Casanova, Jean-Laurent, Conley, Mary Ellen, Seligman, Stephen J., Abel, Laurent, Notarangelo, Luigi D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203950/
https://www.ncbi.nlm.nih.gov/pubmed/25311508
http://dx.doi.org/10.1084/jem.20140520
_version_ 1782340470617145344
author Casanova, Jean-Laurent
Conley, Mary Ellen
Seligman, Stephen J.
Abel, Laurent
Notarangelo, Luigi D.
author_facet Casanova, Jean-Laurent
Conley, Mary Ellen
Seligman, Stephen J.
Abel, Laurent
Notarangelo, Luigi D.
author_sort Casanova, Jean-Laurent
collection PubMed
description Can genetic and clinical findings made in a single patient be considered sufficient to establish a causal relationship between genotype and phenotype? We report that up to 49 of the 232 monogenic etiologies (21%) of human primary immunodeficiencies (PIDs) were initially reported in single patients. The ability to incriminate single-gene inborn errors in immunodeficient patients results from the relative ease in validating the disease-causing role of the genotype by in-depth mechanistic studies demonstrating the structural and functional consequences of the mutations using blood samples. The candidate genotype can be causally connected to a clinical phenotype using cellular (leukocytes) or molecular (plasma) substrates. The recent advent of next generation sequencing (NGS), with whole exome and whole genome sequencing, induced pluripotent stem cell (iPSC) technology, and gene editing technologies—including in particular the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology—offer new and exciting possibilities for the genetic exploration of single patients not only in hematology and immunology but also in other fields. We propose three criteria for deciding if the clinical and experimental data suffice to establish a causal relationship based on only one case. The patient’s candidate genotype must not occur in individuals without the clinical phenotype. Experimental studies must indicate that the genetic variant impairs, destroys, or alters the expression or function of the gene product (or two genetic variants for compound heterozygosity). The causal relationship between the candidate genotype and the clinical phenotype must be confirmed via a relevant cellular phenotype, or by default via a relevant animal phenotype. When supported by satisfaction of rigorous criteria, the report of single patient–based discovery of Mendelian disorders should be encouraged, as it can provide the first step in the understanding of a group of human diseases, thereby revealing crucial pathways underlying physiological and pathological processes.
format Online
Article
Text
id pubmed-4203950
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-42039502015-04-20 Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies Casanova, Jean-Laurent Conley, Mary Ellen Seligman, Stephen J. Abel, Laurent Notarangelo, Luigi D. J Exp Med Perspective Can genetic and clinical findings made in a single patient be considered sufficient to establish a causal relationship between genotype and phenotype? We report that up to 49 of the 232 monogenic etiologies (21%) of human primary immunodeficiencies (PIDs) were initially reported in single patients. The ability to incriminate single-gene inborn errors in immunodeficient patients results from the relative ease in validating the disease-causing role of the genotype by in-depth mechanistic studies demonstrating the structural and functional consequences of the mutations using blood samples. The candidate genotype can be causally connected to a clinical phenotype using cellular (leukocytes) or molecular (plasma) substrates. The recent advent of next generation sequencing (NGS), with whole exome and whole genome sequencing, induced pluripotent stem cell (iPSC) technology, and gene editing technologies—including in particular the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology—offer new and exciting possibilities for the genetic exploration of single patients not only in hematology and immunology but also in other fields. We propose three criteria for deciding if the clinical and experimental data suffice to establish a causal relationship based on only one case. The patient’s candidate genotype must not occur in individuals without the clinical phenotype. Experimental studies must indicate that the genetic variant impairs, destroys, or alters the expression or function of the gene product (or two genetic variants for compound heterozygosity). The causal relationship between the candidate genotype and the clinical phenotype must be confirmed via a relevant cellular phenotype, or by default via a relevant animal phenotype. When supported by satisfaction of rigorous criteria, the report of single patient–based discovery of Mendelian disorders should be encouraged, as it can provide the first step in the understanding of a group of human diseases, thereby revealing crucial pathways underlying physiological and pathological processes. The Rockefeller University Press 2014-10-20 /pmc/articles/PMC4203950/ /pubmed/25311508 http://dx.doi.org/10.1084/jem.20140520 Text en © 2014 Casanova et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Perspective
Casanova, Jean-Laurent
Conley, Mary Ellen
Seligman, Stephen J.
Abel, Laurent
Notarangelo, Luigi D.
Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies
title Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies
title_full Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies
title_fullStr Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies
title_full_unstemmed Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies
title_short Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies
title_sort guidelines for genetic studies in single patients: lessons from primary immunodeficiencies
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203950/
https://www.ncbi.nlm.nih.gov/pubmed/25311508
http://dx.doi.org/10.1084/jem.20140520
work_keys_str_mv AT casanovajeanlaurent guidelinesforgeneticstudiesinsinglepatientslessonsfromprimaryimmunodeficiencies
AT conleymaryellen guidelinesforgeneticstudiesinsinglepatientslessonsfromprimaryimmunodeficiencies
AT seligmanstephenj guidelinesforgeneticstudiesinsinglepatientslessonsfromprimaryimmunodeficiencies
AT abellaurent guidelinesforgeneticstudiesinsinglepatientslessonsfromprimaryimmunodeficiencies
AT notarangeloluigid guidelinesforgeneticstudiesinsinglepatientslessonsfromprimaryimmunodeficiencies